Page 2 - Dr Reddys
We have sole selling rights, beware of fake agents of Sputnik-V: Dr Reddy's
Hyderabad-based pharma major says it isn't supplying Russia jab to residential societies
 "We have sole selling rights, beware of fake agents of Sputnik-V: Dr Reddy's")
DRDO's 2DG anti-Covid drug priced at Rs 990 per sachet: Dr Reddy's
The drug will be provided to government hospitals at a discounted price, ANI quoted government officials as saying.
 "DRDO's 2DG anti-Covid drug priced at Rs 990 per sachet: Dr Reddy's")
Dr Reddy's in talks with RDIF to sell Sputnik V in other countries
Dr Reddys Laboratories is in a pact with Russian Direct Investment Fund to sell 250 million vials of Covid-19 vaccine Sputnik V in India
 "Dr Reddy's in talks with RDIF to sell Sputnik V in other countries")
Stocks to watch: L&T, DRL, UPL, Eicher Motors, Happiest Minds, Tata Power
Royal Enfield said it has decided to shut down its two manufacturing facilities between May 13-16 amid a second Covid wave
 "Stocks to watch: L&T, DRL, UPL, Eicher Motors, Happiest Minds, Tata Power")
Lilly signs 3 pacts to expand availability of baricitinib for Covid patient
Eli Lilly has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy's Ltd, MSN Laboratories and Torrent Pharmaceuticals
 "Lilly signs 3 pacts to expand availability of baricitinib for Covid patient")
Sun Pharma, Dr Reddy's, Aurobindo recall products in the US market
Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling products in the US market, the world's largest market for pharmaceutical products, for various reasons
 "Sun Pharma, Dr Reddy's, Aurobindo recall products in the US market")
Bull Spread strategy on Dr Reddy's Labs by Nandish Shah of HDFC Securities
The stock price has broken out on the daily chart where it closed above 200-day EMA with higher volumes
 "Bull Spread strategy on Dr Reddy's Labs by Nandish Shah of HDFC Securities")
Stocks to watch: Nureca, Max Fin, Axis Bank, DRL, Dredging Corp, Affle
Wipro announced the appointment of Rene Mulder as Country Head and Managing Director of its Switzerland operations
 "Stocks to watch: Nureca, Max Fin, Axis Bank, DRL, Dredging Corp, Affle")
Dr Reddy's launches stomach, esophagus problems treatment drug in US
The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA)
 "Dr Reddy's launches stomach, esophagus problems treatment drug in US")
Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in US
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA)
 "Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in US")
Dr Reddys falls 10% in 2 days, hits over 4-month low post Q3 results
The company said the profits were impacted due to trigger based impairment charge taken on a few acquired products including gNuvaring
 "Dr Reddys falls 10% in 2 days, hits over 4-month low post Q3 results")
Dr Reddy's posts Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore
Dr Reddy's Laboratories on Friday reported a consolidated net profit of Rs 20 crore for the October to December quarter as against a consolidated net loss of Rs 570 crore in the year-ago period.Not accounting for impairment cost, the company's net profit in the quarter would have been at Rs 882 crore, it said.The company's consolidated revenues grew 12 per cent year-on-year to Rs 4,930 crore.There were significant changes to the market conditions for certain of the products fanning part of company's global generics and proprietary products segments, said the company."We continued with our growth momentum while maintaining EBITDA margins. We are progressing well on phase three clinical trials for Sputnik V vaccine in India," said Co-Chairman and Managing Director G V Prasad.The company's revenues in India increased by 26 per cent year-on-year to Rs 959 crore in Q3 FY21. In North America, the sales rose 9 per cent to Rs 1,739 crore.
Dr Reddy's to acquire select brands from Glenmark in Russia, Ukraine
Dr Reddy's Laboratories on Saturday said it had inked a pact with Glenmark Pharmaceuticals to acquire its select anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan
Weekly stock picks by Religare Broking: Buy Aurobindo Pharma, Marico
The chart pattern and positioning of oscillators are pointing towards a sharp up move in Aurobindo Pharma in the near future
 "Weekly stock picks by Religare Broking: Buy Aurobindo Pharma, Marico")
A brief history of Indian companies' tryst with class action suits
Companies ranging from IT to pharmaceuticals have been dragged to courts
 "A brief history of Indian companies' tryst with class action suits")
Sensex ends 134 pts lower, Nifty settles at 11,505; Nifty Pharma jumps 5%
All that happened in the markets today
 "Sensex ends 134 pts lower, Nifty settles at 11,505; Nifty Pharma jumps 5%")
BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs
Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma, and Hikal hit their respective 52-week highs on the BSE
 "BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs")
Russia ropes in Dr Reddy's to sell 100 mn Covid-19 vaccine doses; stk up 4%
Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, Dr Reddy's said in a statement
New launches, patents: Multiple catalysts for Dr Reddy's US business
The ongoing pace of product launches in the US should lead to stronger growth after a good Q1, say analysts
 "New launches, patents: Multiple catalysts for Dr Reddy's US business")
Cipla tweaks management structure to mobilise second level of executives
Do these changes augur well for the future business growth plans? Analysts think so
 "Cipla tweaks management structure to mobilise second level of executives")
